David Kendall MD
MannKind Corporation, Thousand Oaks, California
David M. Kendall, MD, is currently Chief Medical Officer and an Executive Vice President at MannKind Corporation. In this role, Dr. Kendall leads MannKind’s Medical, early and late stage Clinical Development, Pharmacology Research, Regulatory and Safety activities for the corporation.
Dr. Kendall has more than 30 years of experience in diabetes clinical care, education, research and pharmaceutical science. Current responsibilities include medical, research, regulatory, and safety oversight for MannKind’s inhaled mealtime insulin therapy (Technosphere (inhaled human) insulin) and pipeline assets based on the Technosphere platform. He guides clinical, investigator initiated, observational and late phase medical research, development and scientific discovery strategy, late phase clinical development programs, and global medical partnering and regulatory activities. He and his teams are collectively responsibility for scientific thought leader engagement, external medical education, professional relations, medical information and communications.
Prior to joining MannKind in February 2018, Dr. Kendall served as Vice President, Medical Affiars and Distinguished Medical Fellow for Lilly Diabetes (2011-2018). Dr. Kendall also served as Chief Scientific and Medical Officer for the American Diabetes Association (2009-2011) and served in clinical and academic roles as Medical Director and Chief of Clinical and Professional Services at the International Diabetes Center in Minneapolis from 1997-2006 and in 2008-2009. During his tenure at the International Diabetes Center, Dr. Kendall was principle, primary or co-investigator in more than 200 clinical trials.
He served as Executive Medical Director for Amylin Pharmaceuticals from 2005-2008. He has held an academic and clinical appointment as Associate Professor of Medicine at the University of Minnesota from 1997-2005 and 2008-2014 and remained active as a clinician and educator thru 2014.
Dr. Kendall is a professional member of the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD) and the American Association of Clinical Endocrinology (AACE). He has been active in diabetes research, education and clinical care for more than 35 years. His research and clinical interests focus on development and application of novel diabetes advancing the use of unique therapies for diabetes care for both type 1 and type 2 diabetes and its complications. As note, while at the International Diabetes Center, he served as a clinical investigator in numerous industry, foundation and federally sponsored clinical research studies including the NIH sponsored Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) trial in type 1 diabetes and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial in type 2 diabetes.
Dr. Kendall received his bachelor’s degree (BA – 1983) from St. Olaf College in Northfield, Minnesota and his MD (1988) from the University of Minnesota Medical School. He completed internal medicine residency training (1988-92) and diabetes and endocrine fellowship training (1992-1995) - all at the University of Minnesota Medical School.